Polyunsaturated phosphatidylcholine (essentiale) for chronic hepatitis: A systematic review

Chinese Journal of Evidence-Based Medicine

Volumn 5, Issue 7, 2005, Pages 543-548

  Hu, Guo Ping ^a   Liu, Kai ^a   Wang, Su ^a   Tang, Hong ^a   Zhao, Lian San ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Chronic hepatitis; Essentiale; Meta analysis; Polyunsaturated Phosphatidylcholine; Randomized controlled trials; Systematic review

Indexed keywords

CORTISONE; ESSENTIALE; INTERFERON; PLACEBO;

CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HEPATITIS C; HISTOLOGY; HISTOPATHOLOGY; HUMAN; LIVER FUNCTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIRUS HEPATITIS;

EID: 23044488813     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Wang L. The classification of chronic hepatitis - diagnosis, grade and stage[J]. Foreign Medical Sciences: (section of digestive disease), 1995; 15(2): 100-102.
2. Zhang XZ, Gunderman KJ, Wu SM, Chen QN. Therapeutic effect of polyenephosphatidylcholine compound in chronic active hepatitis B in a double-blind randomized controlled trials[J]. Chin J of Pharmacoepidemiology, 1995; 4(1): 4-6.
3. Chinese Infectious and Parasitic Diseases Association and Chinese Liver Diseases Association. The protocol of prevent and treatment of viral hepatitis[J]. Chin J of Infectious Diseases, 2001; 19(1): 56-62.
4. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis[J]. Hepatology, 1981; 1(3): 43.
5. Hepatic Fibrosis Study Group of Chinese Liver Diseases Association. Consensus on evaluation of the diagnosis and efficacy of hepatic fibrosis [J]. Chin J of hepatology, 2002; 10(5): 327.
6. Wang JL, Liu M, Chief Editor. Evidence-based medicine[M]. Peking; The people sanitary publishing company, 2001; 34.
7. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: Is blinding necessary[J]? Control Clin Trials, 1996; 17(34): 1-12.
8. Schulz KF, Charmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials[J]. JAMA, 1995;273(5): 408-412.
9. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in Meta-analyses[J]? Lancet, 1998; 352(9128): 609-613.
10. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses[J]. Annals of Internal Medicine, 2001; 135(11): 982-989.
11. Perter J, Jenkins BP, Portmann A. L, Eddleston W. F, Roger Williams. Use of polyunsaturated phosphatidyl choline in HBsAg negative chronic active hepatitis: results of prospective double blind controlled trial[J]. Liver, 1982; 2(3): 77-81.
12. Kordac V, Brodanova M, Marecek Z, Jirasek AP. Essentiale forte in the treatment of chronic active hepatitis[J]. Prakt Lek (Praha), 1985; 65(43): 834-837.
13. Niederau C, Strohmeyer G, Heintges T, Peter K, Gopfert E (Leich Study Group). Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double blind, placebo controlled trial[J]. Hepato-Gastroenterology, 1998; 45(21): 797-804.
14. Llic V, Begic-Janev. The efficacy of "essential" phospholipids in the therapy of HBsAg + chronic active hepatitis[J]. Med Welt, 1991; 41 (47): 523-525.
15. Wang BE, Li JH, Lin SR, Min J, Zhang LX, Li JH. The multicentral randomized double-blind controlled clinic trials of essentiale for chronic viral hepatitis [R]. (The end report, supplied by avantis) 2000.
16. Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment assignment in controlled clinical trials[J]. N Engl J Med, 1983; 309 (354): 1358-1361.